<p>In-vitro activity.</p>

A 2026 dataset from figshare contains results from screening a library of 618 antiviral compounds for synergistic antifungal activity with amphotericin B against Aspergillus species. The work, authored by Ammar A. Khan, identified 18 initial hits and prioritized two FDA-approved HIV drugs, cobicistat and elvitegravir, for further testing. The data includes fractional inhibitory concentration index (FICI) values, time-kill assay results, and antibiofilm activity measurements across multiple Aspergillus species.

Use Cases

• Identify potential synergistic drug combinations based on FICI values reported for over 90% of Aspergillus fumigatus isolates.
• Analyze the impact of drug combinations on fungal biofilm formation and eradication based on reported 60-80% reductions in biomass.
• Compare antifungal efficacy across different Aspergillus species (A. fumigatus, A. brasiliensis, A. flavus, A. niger, A. terreus) using the provided assay results.
• Evaluate the fungistatic effects of drug combinations over time based on the 48-hour time-kill assay data.

Strengths

• Includes data from screening 618 distinct antiviral compounds.
• Reports specific quantitative results, including FICI values <0.5 for over 90% of Aspergillus fumigatus isolates tested.
• Measures antibiofilm activity, showing up to 80% eradication of mature biofilms with drug combinations.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset is very small at 14.9 KB, indicating limited scope.

Provenance

Source

figshare, authored by Ammar A. Khan.

Collection Method

Laboratory screening of a compound library and subsequent in-vitro assays.

Freshness

Last updated 2026-03-25 17:30:37; freshness should be verified.